Healthy Volunteer
Conditions
Brief summary
This Phase I study is designed to determine the excretion balance of radiocarbon, as the sum of carbon-14 (14C)-labeled TRO19622 and its 14C-metabolites, and to investigate the pharmacokinetics and metabolic profile of TRO19622 (olesoxime) in healthy participants.
Interventions
DRUGOlesoxime
Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
Sponsors
Trophos SA
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
55 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Body mass index (BMI) 20.0 to 28.0 kilograms per meter-squared (kg/m\^2) and body weight at least 60 kilograms (kg) * Fitzpatrick skin type less than (\<) 4 * Good health according to medical history, physical examination, laboratory parameters, vital signs, and 12-lead electrocardiogram (ECG) * Negative urine test for drugs of abuse * Negative alcohol breath test * Negative tests for hepatitis or human immunodeficiency virus (HIV) * Use of effective contraception during and for 3 months beyond study participant, among sexually active non-vasectomized participants with females partners of childbearing potential
Exclusion criteria
* Concomitant or recent medication use within 2 weeks prior to Day 1, except for paracetamol * Use of enzyme-inducing drugs within 2 months prior to Day 1 * Any medical condition that may alter the pharmacokinetics of olesoxime or affect interpretation of study results * Irregular bowel movements * Drug addiction or alcoholism * Use of nicotine products * Participation in another clinical study within 12 weeks prior to Day 1 * Exposure to ionizing radiation within one year prior to Day 1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T1/2 of Radiocarbon | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1 |
| Apparent Plasma Clearance (CL/F) of Olesoxime and Any Major Metabolite(s) Identified | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1 |
| CL/F of Radiocarbon | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1 |
| Apparent Volume of Distribution (Vz/F) of Olesoxime and Any Major Metabolite(s) Identified | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1 |
| Vz/F of Radiocarbon | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1 |
| Cumulative Amount of Olesoxime Excreted in Urine | Continuous urine collection from pre-dose (0 h) to post-dose (432 h, or until release criteria are met) following single dose on Day 1 |
| Cumulative Amount of Olesoxime Excreted in Expired Air | Pre-dose (0 h) and post-dose (8, 10, 12, 16, 24, 48, 72, 96 h) following single dose on Day 1 |
| Cumulative Amount of Olesoxime Excreted in Feces | Continuous fecal collection from pre-dose (0 h) to post-dose (432 h, or until release criteria are met) following single dose on Day 1 |
| Renal Clearance (CLr) of Olesoxime | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1 |
| AUClast of Radiocarbon | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1 |
| AUCinf of Radiocarbon | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1 |
| Percentage of Participants with Adverse Events (AEs) | Continuously from Screening until 7 days after last dose (up to 46 days overall) |
| Maximum Observed Concentration (Cmax) of Olesoxime and Any Major Metabolite(s) Identified | Pre-dose (0 hours [h]) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1 |
| Cmax of Radiocarbon | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1 |
| Time of Maximum Observed Concentration (Tmax) of Olesoxime and Any Major Metabolite(s) Identified | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1 |
| Tmax of Radiocarbon | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1 |
| Area Under the Concentration-Time Curve from Drug Administration to Last Quantifiable Concentration (AUClast) of Olesoxime and Any Major Metabolite(s) Identified | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1 |
| Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Olesoxime and Any Major Metabolite(s) Identified | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1 |
| Elimination Half-Life (t1/2) of Olesoxime and Any Major Metabolite(s) Identified | Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1 |
Outcome results
None listed